Last reviewed · How we verify

Contrast enhanced Ultrasound

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · FDA-approved active Small molecule Quality 5/100

Contrast enhanced Ultrasound is a Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It is currently FDA-approved. Also known as: CEUS, Optison.

At a glance

Generic nameContrast enhanced Ultrasound
Also known asCEUS, Optison
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Contrast enhanced Ultrasound

What is Contrast enhanced Ultrasound?

Contrast enhanced Ultrasound is a Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Who makes Contrast enhanced Ultrasound?

Contrast enhanced Ultrasound is developed and marketed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (see full Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University pipeline at /company/sun-yat-sen-memorial-hospital-of-sun-yat-sen-university).

Is Contrast enhanced Ultrasound also known as anything else?

Contrast enhanced Ultrasound is also known as CEUS, Optison.

What development phase is Contrast enhanced Ultrasound in?

Contrast enhanced Ultrasound is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing